PancraGEN and PanDNA
1 Test, 2 Report Options
| PancraGEN® | PanDNA® | |
|---|---|---|
| Powered by PathfinderTG® with more than 46,000 cysts classified | ||
| Summary of molecular results | ||
| Specific molecular results | ||
| Details of molecular results and what they could mean in clinical context | ||
| Report integrates first-line testing results with molecular data to inform decision-making | ||
| Report provides molecular results for physician integration and interpretation |
An Interpace molecular pathologist provides an in-depth review and explanation of how the clinical information and molecular data were integrated to inform a diagnostic risk category
Interpace provides molecular results and clinicians integrate these results with clinical features to inform diagnostic risk stratification of pancreatic cysts
- Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-146.
- V. Chernyak et al, Incidental pancreatic cystic lesions Radiology 2015 274 161-9
- BU Wu, et al, Prediction of malignancy in cystic neoplasms of the pancreas: a population based cohort study, Am J Gastro 2014 109 121-9
- Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. Diagnostic Pathology. 2016;11:5. doi:10.1186/s13000-016-0462-x.
- Gaujoux S., , Brennan, M., et al. Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-year Time Period. J Am Coll Surg. 2011 April; 212(4): doi:10.1016/j.jamcollsurg.2011.01.016.
- Kaimalkliotis, P., Riff, B., et al. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. Clinical Gastroenterology and Hepatology 2015;13:1808–1815: doi:10.1016/j.cgh.2015.03.017